Literature DB >> 34057463

High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients.

Nathalie Longlune1, Marie Béatrice Nogier1, Marcel Miedougé2, Charlotte Gabilan1, Charles Cartou1, Bruno Seigneuric1, Arnaud Del Bello1, Olivier Marion1,3,4, Stanislas Faguer1,3, Jacques Izopet2,3,4, Nassim Kamar1,3,4.   

Abstract

BACKGROUND: Patients with chronic kidney disease, dialysis patients and kidney-transplant patients are at high risk of developing severe coronavirus disease-19 (COVID-19). Data regarding the immunogenicity of anti-Severe Acute Respiratory Syndrome coronavirus-2 messenger RNA (anti-SARS-CoV-2 mRNA) vaccines in dialysis patients were published recently. We assessed the immunogenicity of anti-SARS-CoV-2 mRNA vaccine in dialysis patients. PATIENTS AND METHODS: One hundred-nine patients on hemodialysis (n = 85) or peritoneal dialysis (n = 24) have received two injections of 30-μg doses of BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech), that were administered intramuscularly 28 days apart. Those who were still seronegative after the second dose were given a third dose one month later. Anti-SARS-CoV-2 antibodies were tested before and after vaccination.
RESULTS: Ninety-one out of the 102 patients who had at least a one-month follow-up after the second (n = 97) or the third (n = 5) vaccine doses had anti-SARS-CoV-2 antibodies. The seroconversion rate was 88.7% (86 out of 97 patients) among SARS-CoV-2 seronegative patients at the initiation of vaccination. Receiving immunosuppressive therapy was an independent predictive factor for non-response to vaccination.
CONCLUSION: Due to high immunogenicity and safety of mRNA vaccines, we strongly recommend prioritizing a two-doses vaccination of dialysis patients. A third dose can be required in non-responders to two doses. When possible, patients waiting for a kidney transplantation, should be offered the vaccine before transplantation.
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; hemodialysis; immunosuppression; peritoneal dialysis; seroconversion

Year:  2021        PMID: 34057463     DOI: 10.1093/ndt/gfab193

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  42 in total

1.  Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.

Authors:  Caroline M Hsu; Daniel E Weiner; Harold J Manley; Gideon N Aweh; Vladimir Ladik; Jill Frament; Dana Miskulin; Christos Argyropoulos; Kenneth Abreo; Andrew Chin; Reginald Gladish; Loay Salman; Doug Johnson; Eduardo K Lacson
Journal:  Clin J Am Soc Nephrol       Date:  2022-02-10       Impact factor: 8.237

2.  Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2- Recovered Dialysis Patients.

Authors:  Philippe Attias; Imane Azzaoui; Khalil El Karoui; Andréa de La Selle; Aurélien Sokal; Pascal Chappert; Philippe Grimbert; Ignacio Fernandez; Magali Bouvier; Chloé Samson; Djamal Dahmane; Philippe Rieu; Patrice Nizard; Slim Fourati; Hamza Sakhi; Matthieu Mahévas
Journal:  Clin J Am Soc Nephrol       Date:  2022-06-28       Impact factor: 10.614

Review 3.  Immune responses to SARS-CoV-2 in dialysis and kidney transplantation.

Authors:  Chiara Cantarelli; Andrea Angeletti; Laura Perin; Luis Sanchez Russo; Gianmarco Sabiu; Manuel Alfredo Podestà; Paolo Cravedi
Journal:  Clin Kidney J       Date:  2022-07-27

4.  Comparison of COVID-19 Inactivated Virus Vaccine Immunogenicity Between Healthy Individuals and Patients on Hemodialysis: A Single-Center Study From Pakistan.

Authors:  Sapna Bai; Murtaza Dhrolia; Hina Qureshi; Ruqaya Qureshi; Kiran Nasir; Aasim Ahmad
Journal:  Cureus       Date:  2022-04-15

5.  ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis.

Authors:  Wisit Prasithsirikul; Tanawin Nopsopon; Phanupong Phutrakool; Pawita Suwanwattana; Piyawat Kantagowit; Wannarat Pongpirul; Anan Jongkaewwattana; Krit Pongpirul
Journal:  Vaccines (Basel)       Date:  2022-06-16

6.  Side Effects and Perceptions of COVID-19 Vaccination in Saudi Arabia: A Cross-Sectional Study.

Authors:  Mohammed Khaled Al-Hanawi; Mpho Keetile; Nasser Akeil Kadasah; Noor Alshareef; Ameerah M N Qattan; Omar Alsharqi
Journal:  Front Med (Lausanne)       Date:  2022-06-07

Review 7.  Humoral and cellular immune response to severe acute respiratory syndrome coronavirus-2 vaccination in haemodialysis and kidney transplant patients.

Authors:  Joel Swai; Ming Gui; Mao Long; Zhu Wei; Zixuan Hu; Shaojun Liu
Journal:  Nephrology (Carlton)       Date:  2021-09-27       Impact factor: 2.358

8.  Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.

Authors:  Georg Beilhack; Rossella Monteforte; Florian Frommlet; Martina Gaggl; Robert Strassl; Andreas Vychytil
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

9.  Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD.

Authors:  Edward J Carr; Andreas Kronbichler; Matthew Graham-Brown; Graham Abra; Christos Argyropoulos; Lorraine Harper; Edgar V Lerma; Rita S Suri; Joel Topf; Michelle Willicombe; Swapnil Hiremath
Journal:  Kidney Int Rep       Date:  2021-07-06

10.  Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients.

Authors:  Simone Cosima Boedecker-Lips; Anja Lautem; Stefan Runkel; Pascal Klimpke; Daniel Kraus; Philipp Keil; Stefan Holtz; Vanessa Tomalla; Paul Marczynski; Christian Benedikt Boedecker; Peter Robert Galle; Martina Koch; Julia Weinmann-Menke
Journal:  Pathogens       Date:  2022-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.